Acadia Pharmaceuticals (ACAD) Work In Process (2018 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Work In Process of $80.7 million for Q1 2026, up 0.87% year-over-year from $80.0 million in Q1 2025, and up 5.23% quarter-over-quarter from $76.7 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Work In Process (2018 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Work In Process history runs 9 years deep, the most recent figure standing at $80.7 million for Q1 2026.
- In Q1 2026, Work In Process rose 0.87% year-over-year to $80.7 million; the TTM figure through Mar 2026 stood at $80.7 million (up 0.87% YoY), while the FY2025 annual figure was $76.7 million, up 9.98% from the prior year.
- Work In Process for Q1 2026 stood at $80.7 million, up from $76.7 million in the prior quarter.
- The five-year high for Work In Process was $84.4 million in Q2 2025, with the low at $4.6 million in Q3 2023.
- The 5-year median for Work In Process is $6.2 million (2022), against an average of $32.8 million.
- The sharpest annual moves came in 2023 and 2024: Work In Process dropped 22.76% in 2023, then surged 1406.94% in 2024.
- Acadia Pharmaceuticals' Work In Process stood at $4.9 million in 2022, then slipped by 6.01% to $4.6 million in 2023, then soared by 1406.94% to $69.7 million in 2024, then gained by 9.98% to $76.7 million in 2025, then grew by 5.23% to $80.7 million in 2026.
- Business Quant data shows ACAD's Work In Process at $80.7 million in Q1 2026, $76.7 million in Q4 2025, and $76.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.30 Mn |
| Mar 31, 2026 | 80.72 Mn |
| Dec 31, 2025 | 76.70 Mn |
| Sep 30, 2025 | 76.89 Mn |
| Jun 30, 2025 | 84.40 Mn |
| Mar 31, 2025 | 80.03 Mn |
| Dec 31, 2024 | 69.74 Mn |
| Sep 30, 2024 | 25.70 Mn |
| Jun 30, 2024 | 14.54 Mn |
| Mar 31, 2024 | 5.55 Mn |
| Dec 31, 2023 | 4.63 Mn |
| Sep 30, 2023 | 4.63 Mn |
| Jun 30, 2023 | 5.31 Mn |
| Mar 31, 2023 | 4.92 Mn |
| Dec 31, 2022 | 4.92 Mn |
| Sep 30, 2022 | 5.99 Mn |
| Jun 30, 2022 | 6.21 Mn |
| Mar 31, 2022 | 6.21 Mn |
| Dec 31, 2021 | 6.22 Mn |
| Sep 30, 2021 | 6.67 Mn |